Congress Materials – American Society of Clinical Oncology (ASCO 2026)
2026 American Society of Clinical Oncology | May 29-Jun 2 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Age and Frailty Analyses of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab + Lenalidomide-Dexamethasone and Bortezomib + Lenalidomide-Dexamethasone
Christopher P. Venner, Sonja Zweegman, Shaji K. Kumar, Thierry Facon, Aurore Perrot, Philippe Moreau, Noopur S. Raje, Cyrille Hulin, Supratik Basu, Vania Hungria, Yael C. Cohen, Hartmut Goldschmidt, George C. Wang, Kasey Bolyard, Lorena Lopez-Masi, Matteo Loi, Fredrik Borgsten, Melissa Rowe, Nizar J. Bahlis, Saad Z. Usmani
This document will be available on May 29th 2026
Amivantamab in recurrent/metastatic head & neck squamous cell cancer after immune checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study
Barbara Burtness, Kevin J. Harrington, Dongmei Ji, Benoit Calderon, Sunmin Lim, Muh-Hwa Yang, Shau-Hsuan Li, Shigenori Kadowaki, Paul Swiecicki, Jessica L. Geiger, William Ince, Dennis Hahn, Ye Guo, Douglas Adkins, Joshua C. Curtin, Kiichiro Toyoizumi, Mark S. Wade, Emrullah Yilmaz, Priya Kim, Ari J. Rosenberg
This document will be available on May 29th 2026
Antitumor Activity of Amivantamab by Consensus Molecular Subtypes in RAS/BRAF Wild‑Type Metastatic Colorectal Cancer: Secondary Analyses From the Phase 1b/2 OrigAMI‑1 Study
Marcia R. Cruz-Correa, Sae-Won Han, Rozita Abdul Malik, Harvey Yu-Li Su, Marc Van den Eynde, Paul E. Oberstein, Ying Yuan, Victor Moreno, Filippo Pietrantonio, Eric X. Chen, Kanwal P. Raghav, Sanjib Chowdhury, Xuesong Lu, Rianka Bhattacharya, Praveen Barala, Cecilia Monge, Seema N. Sethi, Sreenivasa R. Chandana
This document will be available on May 29th 2026
Ciltacabtagene Autoleucel in Lenalidomide‑Refractory Multiple Myeloma Responding to Bridging Therapy: CARTITUDE‑4 Cytogenetic Subgroup Analysis
Roberto Mina, Niels W.C.J. van de Donk, Cyrille Touzeau, Yael C. Cohen, Katja C. Weisel, Wilfried Roeloffzen, Carlos Fernandez de Larrea, Tadao Ishida, P. Joy Ho, Arnab Ghosh, Nina Benachour, Carolina Lonardi, Quanlin Li, Agnes Balogh, Silva Koskinen, Nikoletta Lendvai, Nitin Patel, Paula Rodríguez-Otero, Natlie S. Callander, Salomon Manier
This document will be available on May 29th 2026
Cognition Varies Between Apalutamide + Androgen Deprivation Treatment Responders and Nonresponders
Arun Azad, Marco A. Badillo, Alicia K. Morgans, Dana Rathkopf, Karie Runcie, Geoffrey Gotto, Axel S. Merseburger, Alex Dos Santos, Jingwei Li, Sukie Shopeju, Meenakshi Chatterjee, Rana Zia Ur Rehman, Daniel P. Sanchez, Bhavini Patel, Amitabha Bhaumik, Vasanth Thirugnanam, Yanran Huo, Ashita S. Batavia, Mark A. Wildgust, Neeraj Agarwal
This document will be available on May 29th 2026
COPERNICUS, a pragmatic phase 2b Study of first-line subcutaneous amivantamab + lazertinib with supportive Care in EGFR-mutated advanced NSCLC: early safety results
Sarah B. Goldberg, Balazs Halmos, Narjust Florez, Wade T. Iams, Kartik Konduri, Xiuning Le, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua K. Sabari, Janet C. Tu, David Bjork, Nichelle Stigger, Shiven B. Patel, Annika Hultén, Karen Xia, Paul Cifuentes, Farah Shanoon, Illse Leipoldt, Ticiana Leal
This document will be available after May 29th 2026
COPERNICUS, a pragmatic phase 2b study of subcutaneous amivantamab plus chemotherapy with enhanced dermatologic adverse event prophylaxis in EGFR-mutated advanced NSCLC: Interim results
Ticiana Leal, Balazs Halmos, Narjust Florez, Wade T. Iams, Melissa L. Johnson, Sarah B. Goldberg, Xiuning Le, Sonam Puri, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua K. Sabari, David Bjork, Nichelle Stigger, Ronald Tang, Yichuan Xia, Paul Cifuentes, Farah Shanoon, Illse Leipoldt, Kartik Konduri
This document will be available on May 29th 2026
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of Transplant‑Ineligible (TIE) Patients in the Phase 3 CEPHEUS Study
Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar Jacques J. Bahlis, Christopher P. Venner, Marc J. Braunstein, Luděk Pour, Josep Marti, Supratik Basu, Yael C. Cohen, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Meral Beksaç, Angelo Maiolino, Jaclyn Stanziola, Lorena Lopez-Masi, Matteo Loi, Melissa Rowe, Sonja Zweegman
This document will be available after May 29th 2026
Evaluation of Concomitant Medications in Advanced Prostate Cancer Patients Receiving Apalutamide: TITAN and SPARTAN Post‑Hoc Analysis
Neeraj Agarwal, Geoffrey Gotto, Álvaro Juàrez Soto, Nishant Sangole, Amitabha Bhaumik, Silva Libohova, Alex Yu, Kim N. Chi
This document will be available after May 29th 2026
Immune Effector Cell Associated Enterocolitis (IEC-EC) Incidence and Characterization in Cilta-cel-Treated Patients with RRMM in CARTITUDE Clinical Studies
Yi Lin, Shaozhou K. Tian, Elizabeth Montgomery, Abdullah M. Khan, Serena Rocchi, Elena Zamagni, Wilfried Roeloffzen, Jie Jin, Huabin Sun, Vicki Plaks, Katherine Li, Lee Jablow, Mukta Sharma, Preeti Singh, Nitin Patel, Erin Lee, Bhawna Sharma, Sébastien Anguille, Monique C. Minnema, Christopher S. Strouse
This document will be available after May 29th 2026
KLK2-comPAS: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Pasritamig Plus Best Supportive Care in Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi, Craig Gedye, Laurence Belkoff, Pedro C. Barata, Alice Bernard-Tessier, Julie N. Graff, Nobuaki Matsubara, Shahneen Sandhu, Michael T. Schweizer, Mark N. Stein, Gunhild vVon Amsberg, Bilal A. Siddiqui, Xiao X. Wei, Mina Hosseini, Kassie Kramer, Fouad Moussa, Sherry C. Wang, Shiva Dibaj, Daria L. Gaut, Elena Castro
This document will be available after May 29th 2026
KLK2-PASenger: A Phase 3 Randomized, Open-Label Study of Pasritamig, a T-cell-engager, Targeting Human Kallikrein 2 with Docetaxel versus Docetaxel in Metastatic Castration-Resistant Prostate Cancer
Rana R. McKay, Kai-Jie Yu, Teresa Alonso Gordoa, Johann S. De Bono, Daniel J. George, Boris A. Hadaschik, Aaron R. Hansen, Manish R. Patel, Fred Saad, Armelle Vinceneux, Qiang Wei, Daphne Y. Wu, Mykhailo Tatarenko, Nicky Pieters, Shiva Dibaj, Sherry C. Wang, Dorie A. Capaldi, Victor M. Villalobos, Monica S. Chatwal, Oliver Sartor
This document will be available on May 29th 2026
MajesTEC-9: A Phase 3 Randomized Study of Teclistamab Monotherapy vs Investigator’s Choice of Pomalidomide, Bortezomib, and Dexamethasone or Carfilzomib and Dexamethasone (PVd/Kd) in Patients (Pts) With Relapsed Refractory Multiple Myeloma (RRMM)
Roberto Mina, Cyrille Touzeau, Vania Hungria, Ola Landgren, Divaya Bhutani, Wenming Chen, Swarup Kumar, Chakra P. Chaulagain, Meletios A. Dimopoulos, Nizar J. Bahlis, Senem Maral, Niels W.C.J. van de Donk, Khalid Saja, Raphael Teipel, Miki Ando, Dai Wang, Susan Wroblewski, Priya Shah, Katherine Chastain, Hang Quach
This document will be available on May 29th 2026
New IMS/IMWG Risk Criteria by Next‑Generation Sequencing (NGS): Analysis of Daratumumab Benefit in Both High‑ and Standard‑Risk Patients (Pts) in the PERSEUS Study
Luca Bertamini, Carolina Terragna, Niccolo Bolli, Philippe Moreau, Paula Rodríguez-Otero, Mario Boccadoro, Joan Bladé, Niels W.C.J. van de Donk, Francesca Gay, Roberto Mina, Aurore Perrot, P. Joy Ho, Annemiek Broijl, Meral Beksac, Mark van Duin, Diego Vieyra, Fredrik Borgsten, Melissa Rowe, Meletios A. Dimopoulos, Pieter Sonneveld
This document will be available on May 29th 2026
OrigAMI-5: A Randomized, Phase 3 Study of Amivantamab Plus Pembrolizumab and Carboplatin vs Standard of Care Pembrolizumab Plus Platinum and 5-Fluorouracil as First-Line Treatment in Recurrent/Metastatic Head and Neck Cancer
Robert I. Haddad, Renata Ferrarotto, Ye Guo, Kevin J. Harrington, Lisa F. Licitra, Nabil F. Saba, Makoto Tahara, Pablo Nenclares, Irene Brana, John Xie, Pei-Ling Chu, Mariah Ennis, Jessica Dobbs, Brooke Diorio, Priya Kim, Sujay Shah, Barbara Burtness
This document will be available after May 29th 2026
Overall Survival of First-Line Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results From the CHRYSALIS-2 Study
Joel W. Neal, Byoung Chul Cho, Yongsheng Wang, Lin Wu, Enriqueta Felip, Jiuwei Cui, Alexander I. Spira, Melina E. Marmarelis, Eiki Ichihara, Se-Hoon Lee, James Chih Hsin Yang, Sebastian Y. Michels, Joshua C. Curtin, Xuesong Lyu, Zacharias Anastasiou, Isabelle Leconte, Leonardo Trani, Sujay Shah, Pascale Tomasini
This document will be after May 29th 2026
Perioperative (Neoadjuvant and Adjuvant) Apalutamide (APA) + Androgen Deprivation Therapy (ADT) vs Placebo (PBO) + ADT With Radical Prostatectomy (RP) in High-Risk Localized or Locally Advanced Prostate Cancer (HR LPC/LAPC): Final Analysis of the PROTEUS Phase 3 Study
Mary-Ellen Taplin, Martin Gleave, Neal D. Shore, Angela Lopez-Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Ronaldo Damião, Toshiyuki Kamoto, Ashley Ross, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Alvaro Juárez Soto, Oliver B. Rooney, Shaozhou K. Tian, Lisa Wetherhold, Branko Miladinovic, Sharon McCarthy, Christopher P. Evans, Adam S. Kibel
This document will be available after May 29th 2026
Real-World Treatment Patterns and Overall Survival in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Following Treatment With Immune Checkpoint Inhibitor and Platinum-Based Chemotherapy
Ari J. Rosenberg, Amy (Xiaoqin) Tang, Archan Bhattacharya, Emrullah Yilmaz, Remy B. Verheijen, Levon Demirdjian, Parthiv J. Mahadevia, Paul Swiecicki
This document will be available after May 29th 2026
RP2R Dose Selection of Tal + Tec for the Treatment of EMD Patients in the RedirecTT‑1 Study
Nicholas Au, Dongfen Yuan, Natalia Quijano Cardé, Elvis Danso, Yibo Wang, Yue Guo, Yaming Su, Nahor Haddish-Berhane, Emma C. Scott, Payal Thakkar, Todd Henninger, Mariacristina Festa, Lin Huang, Michelle R. Peterson, Christoph J. Heuck, Jenny Zhang, Indrajeet Singh
This document will be available after May 29th 2026
Validation of Rapid and Deep Prostate-Specific Antigen Decline Among the Latin American Subgroup of LIBERTAS, a Phase 3 Study of Apalutamide Plus Continuous Versus Intermittent Androgen Deprivation Therapy in Metastatic Castration-Sensitive Prostate Cancer
Andrea J. Gomes, Alejandro Lara, Daniel D. Preto, Suelen P. Martins, Jesus David Calvo Dominguez, Pedro M. Domingues, Juan Pablo Feregrino, Jose Mauricio Mota, Rodrigo Pacheco, Livia M. Andrade, Lucas Nogueira, Alex Dos Santos, Sukie Shopeju, Amitabha Bhaumik, Suneel Dinkar Mundle, Sharon McCarthy, Sara Rosas, Mark A. Wildgust, Arun Azad, Neeraj Agarwal
This document will ne available after May 29th 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.